Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation for Female Cancer Patients
1 other identifier
interventional
100
1 country
1
Brief Summary
Ovarian Tissue Cryopreservation will be provided to cancer patients to allow them to have their fertility preserved.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Aug 2023
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 14, 2023
CompletedFirst Posted
Study publicly available on registry
April 26, 2023
CompletedStudy Start
First participant enrolled
August 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2043
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 30, 2043
January 7, 2026
January 1, 2026
19.8 years
April 14, 2023
January 6, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Surgical complications
Surgical complications after ovarian tissue transplantation
15 years
Secondary Outcomes (1)
Pregnancy rate
15 years
Study Arms (1)
Ovarian tissue freezing and subsequent auto-transplantation after thawing
EXPERIMENTALOvarian tissue freezing and subsequent auto-transplantation after thawing
Interventions
Removal of the ovarian tissue will be retrieved via laparoscopic surgery under general anesthesia. The ovarian cortical tissue obtained will be transferred on ice to the laboratory for cryopreservation. After medical treatment, if the patient would like to start a family but has experienced premature ovarian failure, she will have ovarian tissue auto-transplantation after thawing.
Eligibility Criteria
You may qualify if:
- Patients aged from 0-35 years old and diagnosed with cancer e.g., leukaemia, myeloproliferative or myelodysplastic diseases, lymphoma, bone tumours, neurological neoplasms and sarcoma, Paediatric bone marrow transplant patients
- Patients with any illness or who will undergo any type of treatment that may cause irreversible damage to their fertility, such as extensive abdominal surgery, high toxicity medication and treatments;
- Patients suffering from hormone-sensitive malignancies who will undergo medical treatment, such as radiotherapy and chemotherapy that is liable to damage their ovaries and deter them from conception in the future.
You may not qualify if:
- Patients with no anticipated oncologic therapies
- Patients who are pregnant
- Children with one ovary
- Children deemed high risk for perioperative complications
- Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Prince of Wales Hospital
Hong Kong, Hong Kong
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
Jacqueline Pui Wah CHUNG, MBBS
Chinese University of Hong Kong
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
April 14, 2023
First Posted
April 26, 2023
Study Start
August 1, 2023
Primary Completion (Estimated)
April 30, 2043
Study Completion (Estimated)
December 30, 2043
Last Updated
January 7, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share